Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 120

1.

Dissecting Prognostic From Predictive Utility: Circulating AR-V7 Biomarker Testing for Advanced Prostate Cancer.

Sharp A, Porta N, Lambros MBK, Welti JC, Paschalis A, Raj GV, Plymate SP, de Bono JS.

J Clin Oncol. 2019 Jul 2:JCO1901104. doi: 10.1200/JCO.19.01104. [Epub ahead of print] No abstract available.

PMID:
31265359
2.

Clinical Utility of Circulating Tumour Cell Androgen Receptor Splice Variant-7 Status in Metastatic Castration-resistant Prostate Cancer.

Sharp A, Welti JC, Lambros MBK, Dolling D, Rodrigues DN, Pope L, Aversa C, Figueiredo I, Fraser J, Ahmad Z, Lu C, Rescigno P, Kolinsky M, Bertan C, Seed G, Riisnaes R, Miranda S, Crespo M, Pereira R, Ferreira A, Fowler G, Ebbs B, Flohr P, Neeb A, Bianchini D, Petremolo A, Sumanasuriya S, Paschalis A, Mateo J, Tunariu N, Yuan W, Carreira S, Plymate SR, Luo J, de Bono JS.

Eur Urol. 2019 Apr 27. pii: S0302-2838(19)30285-4. doi: 10.1016/j.eururo.2019.04.006. [Epub ahead of print]

3.

Immunogenomic analyses associate immunological alterations with mismatch repair defects in prostate cancer.

Rodrigues DN, Rescigno P, Liu D, Yuan W, Carreira S, Lambros MB, Seed G, Mateo J, Riisnaes R, Mullane S, Margolis C, Miao D, Miranda S, Dolling D, Clarke M, Bertan C, Crespo M, Boysen G, Ferreira A, Sharp A, Figueiredo I, Keliher D, Aldubayan S, Burke KP, Sumanasuriya S, Fontes MS, Bianchini D, Zafeiriou Z, Mendes LST, Mouw K, Schweizer MT, Pritchard CC, Salipante S, Taplin ME, Beltran H, Rubin MA, Cieslik M, Robinson D, Heath E, Schultz N, Armenia J, Abida W, Scher H, Lord C, D'Andrea A, Sawyers CL, Chinnaiyan AM, Alimonti A, Nelson PS, Drake CG, Van Allen EM, de Bono JS.

J Clin Invest. 2018 Nov 1;128(11):5185. doi: 10.1172/JCI125184. Epub 2018 Nov 1. No abstract available.

4.

Immunogenomic analyses associate immunological alterations with mismatch repair defects in prostate cancer.

Nava Rodrigues D, Rescigno P, Liu D, Yuan W, Carreira S, Lambros MB, Seed G, Mateo J, Riisnaes R, Mullane S, Margolis C, Miao D, Miranda S, Dolling D, Clarke M, Bertan C, Crespo M, Boysen G, Ferreira A, Sharp A, Figueiredo I, Keliher D, Aldubayan S, Burke KP, Sumanasuriya S, Fontes MS, Bianchini D, Zafeiriou Z, Teixeira Mendes LS, Mouw K, Schweizer MT, Pritchard CC, Salipante S, Taplin ME, Beltran H, Rubin MA, Cieslik M, Robinson D, Heath E, Schultz N, Armenia J, Abida W, Scher H, Lord C, D'Andrea A, Sawyers CL, Chinnaiyan AM, Alimonti A, Nelson PS, Drake CG, Van Allen EM, de Bono JS.

J Clin Invest. 2018 Oct 1;128(10):4441-4453. doi: 10.1172/JCI121924. Epub 2018 Sep 4. Erratum in: J Clin Invest. 2018 Nov 1;128(11):5185.

5.

Single-Cell Analyses of Prostate Cancer Liquid Biopsies Acquired by Apheresis.

Lambros MB, Seed G, Sumanasuriya S, Gil V, Crespo M, Fontes M, Chandler R, Mehra N, Fowler G, Ebbs B, Flohr P, Miranda S, Yuan W, Mackay A, Ferreira A, Pereira R, Bertan C, Figueiredo I, Riisnaes R, Rodrigues DN, Sharp A, Goodall J, Boysen G, Carreira S, Bianchini D, Rescigno P, Zafeiriou Z, Hunt J, Moloney D, Hamilton L, Neves RP, Swennenhuis J, Andree K, Stoecklein NH, Terstappen LWMM, de Bono JS.

Clin Cancer Res. 2018 Nov 15;24(22):5635-5644. doi: 10.1158/1078-0432.CCR-18-0862. Epub 2018 Aug 9.

PMID:
30093450
6.

Toward a real liquid biopsy in metastatic breast and prostate cancer: Diagnostic LeukApheresis increases CTC yields in a European prospective multicenter study (CTCTrap).

Andree KC, Mentink A, Zeune LL, Terstappen LWMM, Stoecklein NH, Neves RP, Driemel C, Lampignano R, Yang L, Neubauer H, Fehm T, Fischer JC, Rossi E, Manicone M, Basso U, Marson P, Zamarchi R, Loriot Y, Lapierre V, Faugeroux V, Oulhen M, Farace F, Fowler G, Sousa Fontes M, Ebbs B, Lambros M, Crespo M, Flohr P, de Bono JS.

Int J Cancer. 2018 Nov 15;143(10):2584-2591. doi: 10.1002/ijc.31752. Epub 2018 Sep 19.

PMID:
30006930
7.

CRISPR screens identify genomic ribonucleotides as a source of PARP-trapping lesions.

Zimmermann M, Murina O, Reijns MAM, Agathanggelou A, Challis R, Tarnauskaitė Ž, Muir M, Fluteau A, Aregger M, McEwan A, Yuan W, Clarke M, Lambros MB, Paneesha S, Moss P, Chandrashekhar M, Angers S, Moffat J, Brunton VG, Hart T, de Bono J, Stankovic T, Jackson AP, Durocher D.

Nature. 2018 Jul;559(7713):285-289. doi: 10.1038/s41586-018-0291-z. Epub 2018 Jul 4.

8.

IL-23 secreted by myeloid cells drives castration-resistant prostate cancer.

Calcinotto A, Spataro C, Zagato E, Di Mitri D, Gil V, Crespo M, De Bernardis G, Losa M, Mirenda M, Pasquini E, Rinaldi A, Sumanasuriya S, Lambros MB, Neeb A, Lucianò R, Bravi CA, Nava-Rodrigues D, Dolling D, Prayer-Galetti T, Ferreira A, Briganti A, Esposito A, Barry S, Yuan W, Sharp A, de Bono J, Alimonti A.

Nature. 2018 Jul;559(7714):363-369. doi: 10.1038/s41586-018-0266-0. Epub 2018 Jun 27.

9.

A streamlined workflow for single-cells genome-wide copy-number profiling by low-pass sequencing of LM-PCR whole-genome amplification products.

Ferrarini A, Forcato C, Buson G, Tononi P, Del Monaco V, Terracciano M, Bolognesi C, Fontana F, Medoro G, Neves R, Möhlendick B, Rihawi K, Ardizzoni A, Sumanasuriya S, Flohr P, Lambros M, de Bono J, Stoecklein NH, Manaresi N.

PLoS One. 2018 Mar 1;13(3):e0193689. doi: 10.1371/journal.pone.0193689. eCollection 2018.

10.

Molecular Mechanism of Resveratrol's Lipid Membrane Protection.

Fei Q, Kent D, Botello-Smith WM, Nur F, Nur S, Alsamarah A, Chatterjee P, Lambros M, Luo Y.

Sci Rep. 2018 Jan 25;8(1):1587. doi: 10.1038/s41598-017-18943-1.

11.

Mapping genetic vulnerabilities reveals BTK as a novel therapeutic target in oesophageal cancer.

Chong IY, Aronson L, Bryant H, Gulati A, Campbell J, Elliott R, Pettitt S, Wilkerson P, Lambros MB, Reis-Filho JS, Ramessur A, Davidson M, Chau I, Cunningham D, Ashworth A, Lord CJ.

Gut. 2018 Oct;67(10):1780-1792. doi: 10.1136/gutjnl-2017-314408. Epub 2017 Aug 22.

12.

Application of Liquid Biopsies in Cancer Targeted Therapy.

Sumanasuriya S, Lambros MB, de Bono JS.

Clin Pharmacol Ther. 2017 Nov;102(5):745-747. doi: 10.1002/cpt.764. Epub 2017 Jul 29. Review.

13.

Gene Copy Number Estimation from Targeted Next-Generation Sequencing of Prostate Cancer Biopsies: Analytic Validation and Clinical Qualification.

Seed G, Yuan W, Mateo J, Carreira S, Bertan C, Lambros M, Boysen G, Ferraldeschi R, Miranda S, Figueiredo I, Riisnaes R, Crespo M, Rodrigues DN, Talevich E, Robinson DR, Kunju LP, Wu YM, Lonigro R, Sandhu S, Chinnaiyan M, de Bono JS.

Clin Cancer Res. 2017 Oct 15;23(20):6070-6077. doi: 10.1158/1078-0432.CCR-17-0972. Epub 2017 Jul 27. Erratum in: Clin Cancer Res. 2018 May 1;24(9):2234.

14.

Analysis of DNA methylation in single circulating tumor cells.

Pixberg CF, Raba K, Müller F, Behrens B, Honisch E, Niederacher D, Neubauer H, Fehm T, Goering W, Schulz WA, Flohr P, Boysen G, Lambros M, De Bono JS, Knoefel WT, Sproll C, Stoecklein NH, Neves RPL.

Oncogene. 2017 Jun 8;36(23):3223-3231. doi: 10.1038/onc.2016.480. Epub 2017 Jan 9.

PMID:
28068321
15.

Preclinical evaluation of the PARP inhibitor BMN-673 for the treatment of ovarian clear cell cancer.

Wilkerson PM, Dedes KJ, Samartzis EP, Dedes I, Lambros MB, Natrajan R, Gauthier A, Piscuoglio S, Töpfer C, Vukovic V, Daley F, Weigelt B, Reis-Filho JS.

Oncotarget. 2017 Jan 24;8(4):6057-6066. doi: 10.18632/oncotarget.14011.

16.

Fluorescent Orthotopic Mouse Model of Pancreatic Cancer.

Moreno JA, Sanchez A, Hoffman RM, Nur S, Lambros MP.

J Vis Exp. 2016 Sep 20;(115). doi: 10.3791/54337.

17.

Preclinical medical student observations associated with later professionalism concerns.

Burns CA, Lambros MA, Atkinson HH, Russell G, Fitch MT.

Med Teach. 2017 Jan;39(1):38-43. doi: 10.1080/0142159X.2016.1230185. Epub 2016 Sep 16.

PMID:
27636372
18.

Genome wide expression after different doses of irradiation of a three-dimensional (3D) model of oral mucosal.

Lambros MP, DeSalvo MK, Mulamalla HC, Moreno J, Kondapalli L.

Genom Data. 2015 Dec 19;7:137-9. doi: 10.1016/j.gdata.2015.12.013. eCollection 2016 Mar.

19.

DNA Copy Number Aberrations, and Human Papillomavirus Status in Penile Carcinoma. Clinico-Pathological Correlations and Potential Driver Genes.

La-Touche S, Lemetre C, Lambros M, Stankiewicz E, Ng CK, Weigelt B, Rajab R, Tinwell B, Corbishley C, Watkin N, Berney D, Reis-Filho JS.

PLoS One. 2016 Feb 22;11(2):e0146740. doi: 10.1371/journal.pone.0146740. eCollection 2016.

20.

The status of epidermal growth factor receptor in borderline ovarian tumours.

Showeil R, Romano C, Valganon M, Lambros M, Trivedi P, Van Noorden S, Sriraksa R, El-Kaffash D, El-Etreby N, Natrajan R, Foroni L, Osborne R, El-Bahrawy M.

Oncotarget. 2016 Mar 1;7(9):10568-77. doi: 10.18632/oncotarget.7257.

21.

Transcriptional profiling of radiation damage and preventive treatments in a 3-dimensional (3D) human cell culture model of oral mucositis.

Lambros MP, DeSalvo MK, Moreno J, Mulamalla HC, Kondapalli L.

Genom Data. 2015 Aug 4;6:40-3. doi: 10.1016/j.gdata.2015.07.029. eCollection 2015 Dec.

22.

Oxidative Stress and the Nrf2 Anti-Oxidant Transcription Factor in Age-Related Macular Degeneration.

Lambros ML, Plafker SM.

Adv Exp Med Biol. 2016;854:67-72. doi: 10.1007/978-3-319-17121-0_10. Review.

23.

Ovarian carcinoma patient derived xenografts reproduce their tumor of origin and preserve an oligoclonal structure.

Colombo PE, du Manoir S, Orsett B, Bras-Gonçalves R, Lambros MB, MacKay A, Nguyen TT, Boissière F, Pourquier D, Bibeau F, Reis-Filho JS, Theillet C.

Oncotarget. 2015 Sep 29;6(29):28327-40. doi: 10.18632/oncotarget.5069.

24.

Molecular signatures in the prevention of radiation damage by the synergistic effect of N-acetyl cysteine and qingre liyan decoction, a traditional chinese medicine, using a 3-dimensional cell culture model of oral mucositis.

Lambros MP, Kondapalli L, Parsa C, Mulamalla HC, Orlando R, Pon D, Huang Y, Chow MS.

Evid Based Complement Alternat Med. 2015;2015:425760. doi: 10.1155/2015/425760. Epub 2015 Jan 29.

25.

Molecular characterisation of isogenic taxane resistant cell lines identify novel drivers of drug resistance.

Kenicer J, Spears M, Lyttle N, Taylor KJ, Liao L, Cunningham CA, Lambros M, MacKay A, Yao C, Reis-Filho J, Bartlett JM.

BMC Cancer. 2014 Oct 14;14:762. doi: 10.1186/1471-2407-14-762.

26.

Unbiased analysis of potential targets of breast cancer susceptibility loci by Capture Hi-C.

Dryden NH, Broome LR, Dudbridge F, Johnson N, Orr N, Schoenfelder S, Nagano T, Andrews S, Wingett S, Kozarewa I, Assiotis I, Fenwick K, Maguire SL, Campbell J, Natrajan R, Lambros M, Perrakis E, Ashworth A, Fraser P, Fletcher O.

Genome Res. 2014 Nov;24(11):1854-68. doi: 10.1101/gr.175034.114. Epub 2014 Aug 13.

27.

Characterization of the genomic features and expressed fusion genes in micropapillary carcinomas of the breast.

Natrajan R, Wilkerson PM, Marchiò C, Piscuoglio S, Ng CK, Wai P, Lambros MB, Samartzis EP, Dedes KJ, Frankum J, Bajrami I, Kopec A, Mackay A, A'hern R, Fenwick K, Kozarewa I, Hakas J, Mitsopoulos C, Hardisson D, Lord CJ, Kumar-Sinha C, Ashworth A, Weigelt B, Sapino A, Chinnaiyan AM, Maher CA, Reis-Filho JS.

J Pathol. 2014 Apr;232(5):553-65. doi: 10.1002/path.4325. Epub 2014 Feb 5.

28.

Determination of HER2 amplification status on tumour DNA by digital PCR.

Garcia-Murillas I, Lambros M, Turner NC.

PLoS One. 2013 Dec 26;8(12):e83409. doi: 10.1371/journal.pone.0083409. eCollection 2013.

29.

The genomic landscape of oesophagogastric junctional adenocarcinoma.

Chong IY, Cunningham D, Barber LJ, Campbell J, Chen L, Kozarewa I, Fenwick K, Assiotis I, Guettler S, Garcia-Murillas I, Awan S, Lambros M, Starling N, Wotherspoon A, Stamp G, Gonzalez-de-Castro D, Benson M, Chau I, Hulkki S, Nohadani M, Eltahir Z, Lemnrau A, Orr N, Rao S, Lord CJ, Ashworth A.

J Pathol. 2013 Nov;231(3):301-10.

PMID:
24308032
30.

Genomic profiling of histological special types of breast cancer.

Horlings HM, Weigelt B, Anderson EM, Lambros MB, Mackay A, Natrajan R, Ng CK, Geyer FC, van de Vijver MJ, Reis-Filho JS.

Breast Cancer Res Treat. 2013 Nov;142(2):257-69. doi: 10.1007/s10549-013-2740-6. Epub 2013 Oct 27.

PMID:
24162157
31.

PI3K pathway dependencies in endometrioid endometrial cancer cell lines.

Weigelt B, Warne PH, Lambros MB, Reis-Filho JS, Downward J.

Clin Cancer Res. 2013 Jul 1;19(13):3533-44. doi: 10.1158/1078-0432.CCR-12-3815. Epub 2013 May 14.

32.

Identification of novel determinants of resistance to lapatinib in ERBB2-amplified cancers.

Wetterskog D, Shiu KK, Chong I, Meijer T, Mackay A, Lambros M, Cunningham D, Reis-Filho JS, Lord CJ, Ashworth A.

Oncogene. 2014 Feb 20;33(8):966-76. doi: 10.1038/onc.2013.41. Epub 2013 Mar 11.

PMID:
23474757
33.

Mutation profiling of adenoid cystic carcinomas from multiple anatomical sites identifies mutations in the RAS pathway, but no KIT mutations.

Wetterskog D, Wilkerson PM, Rodrigues DN, Lambros MB, Fritchie K, Andersson MK, Natrajan R, Gauthier A, Di Palma S, Shousha S, Gatalica Z, Töpfer C, Vukovic V, A'Hern R, Weigelt B, Vincent-Salomon A, Stenman G, Rubin BP, Reis-Filho JS.

Histopathology. 2013 Mar;62(4):543-50. doi: 10.1111/his.12050. Epub 2013 Feb 12.

34.

Integrative molecular and functional profiling of ERBB2-amplified breast cancers identifies new genetic dependencies.

Shiu KK, Wetterskog D, Mackay A, Natrajan R, Lambros M, Sims D, Bajrami I, Brough R, Frankum J, Sharpe R, Marchio C, Horlings H, Reyal F, van der Vijver M, Turner N, Reis-Filho JS, Lord CJ, Ashworth A.

Oncogene. 2014 Jan 30;33(5):619-31. doi: 10.1038/onc.2012.625. Epub 2013 Jan 21.

35.

Somatic complex I disruptive mitochondrial DNA mutations are modifiers of tumorigenesis that correlate with low genomic instability in pituitary adenomas.

Kurelac I, MacKay A, Lambros MB, Di Cesare E, Cenacchi G, Ceccarelli C, Morra I, Melcarne A, Morandi L, Calabrese FM, Attimonelli M, Tallini G, Reis-Filho JS, Gasparre G.

Hum Mol Genet. 2013 Jan 15;22(2):226-38. doi: 10.1093/hmg/dds422. Epub 2012 Oct 9.

PMID:
23049073
36.

The cystine/glutamate antiporter system x(c)(-) in health and disease: from molecular mechanisms to novel therapeutic opportunities.

Lewerenz J, Hewett SJ, Huang Y, Lambros M, Gout PW, Kalivas PW, Massie A, Smolders I, Methner A, Pergande M, Smith SB, Ganapathy V, Maher P.

Antioxid Redox Signal. 2013 Feb 10;18(5):522-55. doi: 10.1089/ars.2011.4391. Epub 2012 Aug 3. Review.

37.

Genomic characterisation of acral melanoma cell lines.

Furney SJ, Turajlic S, Fenwick K, Lambros MB, MacKay A, Ricken G, Mitsopoulos C, Kozarewa I, Hakas J, Zvelebil M, Lord CJ, Ashworth A, Reis-Filho JS, Herlyn M, Murata H, Marais R.

Pigment Cell Melanoma Res. 2012 Jul;25(4):488-92. doi: 10.1111/j.1755-148X.2012.01016.x.

PMID:
22578220
38.

Molecular evidence in support of the neoplastic and precursor nature of microglandular adenosis.

Geyer FC, Lacroix-Triki M, Colombo PE, Patani N, Gauthier A, Natrajan R, Lambros MB, Khalifeh I, Albarracin C, Orru S, Marchiò C, Sapino A, Mackay A, Weigelt B, Schmitt FC, Wesseling J, Sneige N, Reis-Filho JS.

Histopathology. 2012 May;60(6B):E115-30. doi: 10.1111/j.1365-2559.2012.04207.x. Epub 2012 Apr 4.

39.

Functional characterization of the 19q12 amplicon in grade III breast cancers.

Natrajan R, Mackay A, Wilkerson PM, Lambros MB, Wetterskog D, Arnedos M, Shiu KK, Geyer FC, Langerød A, Kreike B, Reyal F, Horlings HM, van de Vijver MJ, Palacios J, Weigelt B, Reis-Filho JS.

Breast Cancer Res. 2012 Mar 20;14(2):R53.

40.

A whole-genome massively parallel sequencing analysis of BRCA1 mutant oestrogen receptor-negative and -positive breast cancers.

Natrajan R, Mackay A, Lambros MB, Weigelt B, Wilkerson PM, Manie E, Grigoriadis A, A'Hern R, van der Groep P, Kozarewa I, Popova T, Mariani O, Turaljic S, Furney SJ, Marais R, Rodruigues DN, Flora AC, Wai P, Pawar V, McDade S, Carroll J, Stoppa-Lyonnet D, Green AR, Ellis IO, Swanton C, van Diest P, Delattre O, Lord CJ, Foulkes WD, Vincent-Salomon A, Ashworth A, Stern MH, Reis-Filho JS.

J Pathol. 2012 May;227(1):29-41. doi: 10.1002/path.4003. Epub 2012 Feb 23.

41.

RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors.

Su F, Viros A, Milagre C, Trunzer K, Bollag G, Spleiss O, Reis-Filho JS, Kong X, Koya RC, Flaherty KT, Chapman PB, Kim MJ, Hayward R, Martin M, Yang H, Wang Q, Hilton H, Hang JS, Noe J, Lambros M, Geyer F, Dhomen N, Niculescu-Duvaz I, Zambon A, Niculescu-Duvaz D, Preece N, Robert L, Otte NJ, Mok S, Kee D, Ma Y, Zhang C, Habets G, Burton EA, Wong B, Nguyen H, Kockx M, Andries L, Lestini B, Nolop KB, Lee RJ, Joe AK, Troy JL, Gonzalez R, Hutson TE, Puzanov I, Chmielowski B, Springer CJ, McArthur GA, Sosman JA, Lo RS, Ribas A, Marais R.

N Engl J Med. 2012 Jan 19;366(3):207-15. doi: 10.1056/NEJMoa1105358.

42.

Genomic and mutational profiling of ductal carcinomas in situ and matched adjacent invasive breast cancers reveals intra-tumour genetic heterogeneity and clonal selection.

Hernandez L, Wilkerson PM, Lambros MB, Campion-Flora A, Rodrigues DN, Gauthier A, Cabral C, Pawar V, Mackay A, A'Hern R, Marchiò C, Palacios J, Natrajan R, Weigelt B, Reis-Filho JS.

J Pathol. 2012 May;227(1):42-52. doi: 10.1002/path.3990. Epub 2012 Mar 21.

43.

Whole genome sequencing of matched primary and metastatic acral melanomas.

Turajlic S, Furney SJ, Lambros MB, Mitsopoulos C, Kozarewa I, Geyer FC, Mackay A, Hakas J, Zvelebil M, Lord CJ, Ashworth A, Thomas M, Stamp G, Larkin J, Reis-Filho JS, Marais R.

Genome Res. 2012 Feb;22(2):196-207. doi: 10.1101/gr.125591.111. Epub 2011 Dec 19.

44.

Functionally recurrent rearrangements of the MAST kinase and Notch gene families in breast cancer.

Robinson DR, Kalyana-Sundaram S, Wu YM, Shankar S, Cao X, Ateeq B, Asangani IA, Iyer M, Maher CA, Grasso CS, Lonigro RJ, Quist M, Siddiqui J, Mehra R, Jing X, Giordano TJ, Sabel MS, Kleer CG, Palanisamy N, Natrajan R, Lambros MB, Reis-Filho JS, Kumar-Sinha C, Chinnaiyan AM.

Nat Med. 2011 Nov 20;17(12):1646-51. doi: 10.1038/nm.2580.

45.

Identification of gene fusion transcripts by transcriptome sequencing in BRCA1-mutated breast cancers and cell lines.

Ha KC, Lalonde E, Li L, Cavallone L, Natrajan R, Lambros MB, Mitsopoulos C, Hakas J, Kozarewa I, Fenwick K, Lord CJ, Ashworth A, Vincent-Salomon A, Basik M, Reis-Filho JS, Majewski J, Foulkes WD.

BMC Med Genomics. 2011 Oct 27;4:75. doi: 10.1186/1755-8794-4-75.

46.

Immunophenotypic and genomic characterization of papillary carcinomas of the breast.

Duprez R, Wilkerson PM, Lacroix-Triki M, Lambros MB, MacKay A, A'Hern R, Gauthier A, Pawar V, Colombo PE, Daley F, Natrajan R, Ward E, MacGrogan G, Arbion F, Michenet P, Weigelt B, Vincent-Salomon A, Reis-Filho JS.

J Pathol. 2012 Feb;226(3):427-441. doi: 10.1002/path.3032. Epub 2011 Dec 9.

47.

Adenoid cystic carcinomas constitute a genomically distinct subgroup of triple-negative and basal-like breast cancers.

Wetterskog D, Lopez-Garcia MA, Lambros MB, A'Hern R, Geyer FC, Milanezi F, Cabral MC, Natrajan R, Gauthier A, Shiu KK, Orr N, Shousha S, Gatalica Z, Mackay A, Palacios J, Reis-Filho JS, Weigelt B.

J Pathol. 2012 Jan;226(1):84-96. doi: 10.1002/path.2974. Epub 2011 Oct 20.

PMID:
22015727
48.

Functional viability profiles of breast cancer.

Brough R, Frankum JR, Sims D, Mackay A, Mendes-Pereira AM, Bajrami I, Costa-Cabral S, Rafiq R, Ahmad AS, Cerone MA, Natrajan R, Sharpe R, Shiu KK, Wetterskog D, Dedes KJ, Lambros MB, Rawjee T, Linardopoulos S, Reis-Filho JS, Turner NC, Lord CJ, Ashworth A.

Cancer Discov. 2011 Aug;1(3):260-73. doi: 10.1158/2159-8290.CD-11-0107. Epub 2011 Aug 2.

49.

Non-existence of caveolin-1 gene mutations in human breast cancer.

Patani N, Lambros MB, Natrajan R, Dedes KJ, Geyer FC, Ward E, Martin LA, Dowsett M, Reis-Filho JS.

Breast Cancer Res Treat. 2012 Jan;131(1):307-10. doi: 10.1007/s10549-011-1761-2. Epub 2011 Sep 11.

PMID:
21909981
50.

High-throughput detection of fusion genes in cancer using the Sequenom MassARRAY platform.

Lambros MB, Wilkerson PM, Natrajan R, Patani N, Pawar V, Vatcheva R, Mansour M, Laschet M, Oelze B, Orr N, Muller S, Reis-Filho JS.

Lab Invest. 2011 Oct;91(10):1491-501. doi: 10.1038/labinvest.2011.110. Epub 2011 Aug 1.

Supplemental Content

Loading ...
Support Center